• Sandoz, a Novartis division, the pioneer and global leader in biosimilars acquired the rights from Pfizer for the development, commercialization and manufacture of PF-06438179 in the 28 countries that form the European Economic Area (EEA)* in February 2016 where it is known as GP1111.
• The confirmatory study (REFLECTIONS B537-02), evaluating the efficacy, safety and immunogenicity of PF-06438179 (biosimilar infliximab) to reference product Remicade® (infliximab), met its primary endpoint.
• Results demonstrate equivalent efficacy as measured by the American College of …

• New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®.
• Study highlights importance of improving treatment “persistence” over time for long-term respiratory diseases.
• Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.

[1] Seretide® and Diskus® are registered trademarks owned by Glaxo Group Ltd.

Holzkirchen, August 31, 2016 – New data just …

• Erelzi is approved for all indications included in the reference product’s label
   
• Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine
   
• Erelzi is the second biosimilar from Sandoz to receive FDA approval in the US, building upon established global leadership in biosimilars

Holzkirchen, August 30, 2016 – Sandoz, a Novartis division and the global leader in biosimilars, announced today that the US Food and Drug Administration (FDA …

• First-of-a-kind service for healthcare professionals will offer access to latest news from leading international transplantation congress.
• Transplant TODAY online service will be launched at this month’s International Congress of the Transplantation Society (TTS).
• Sandoz, the leading global supplier of generic transplantation medicines, collaborates with international experts to offer this service.

Holzkirchen, August 9, 2016 – Sandoz today announces the launch of a novel online medical education platform, Transplant TODAY, offering access …

• Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product
• Committee’s recommendation based on totality of evidence from global development program showing biosimilar etanercept is highly similar to Enbrel^®*

Holzkirchen, 13 July, 2016. Sandoz, a Novartis division and leader in biosimilars, announced today that the US Food and Drug Administration (FDA) Arthritis Advisory Committee recommended approval of its proposed biosimilar etanercept. The committee voted unanimously ( …